Several biopharmaceutical companies have already selected Crucell's STAR^® technology to develop their own products across a wide range of therapeutic areas. Current partners and licensees include Genzyme, Xoma, UCB Celltech, Novartis and Novo Nordisk.

STAR^® licensees – whether research or commercial – receive a high level of support from Crucell in their product development programs.

In the field of recombinant human antibodies and proteins, Crucell seeks partners for co-development collaborations.

For more information on partnering opportunities in relation to STAR^® technology, please visit the Partners section of our website.